Streetbeat News

Products Services

GANX

Gain Therapeutics has initiated the Phase 1 trial of GT-02287, a treatment for GBA1 Parkinson's disease, with the first two subjects already dosed. The company anticipates the completion of the trial in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:15 am

UBER

Uber has announced a new feature called 'Return a Package', which allows customers to have a courier pick up their prepaid and sealed packages and drop them off at a local post office, UPS, or FedEx. The service is available in over 4,950 cities across the United States. Uber One members can avail this service for a flat fee of $3, while others will be charged $5.

Portfolio Pulse from Charles Gross

October 04, 2023 | 11:12 am

MRNA

Moderna has announced Phase 1/2 data from mRNA-1083, a combination vaccine against Influenza and COVID-19. The results show strong immunogenicity and an acceptable reactogenicity and safety profile compared to standalone vaccines.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:11 am

AQMS

6K Energy and Aqua Metals are collaborating to build the first circular supply chain of critical minerals for lithium battery manufacturing in the US. This partnership aims to enhance the sustainability and efficiency of lithium battery production.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:11 am

IONS

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is holding an investor and analyst event, Ionis Innovation Day, in New York City. The event will feature presentations from Ionis leaders and external physicians, highlighting the company's integrated research, development, and commercialization capabilities, as well as key pipeline and technology highlights.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:10 am

PYPD

PolyPid Ltd. (NASDAQ:PYPD) has published positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. The safety and toxicokinetics of D-PLEX100 were tested in juvenile swine for a period of nine months with no treatment-related adverse events observed. PolyPid's ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:09 am

PRTC

PureTech Health's founded entity, Vedanta Biosciences, has dosed the first patient in a Phase 2 clinical trial of VE202 for the treatment of ulcerative colitis. The U.S. FDA has granted Fast Track designation to VE202, which is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:06 am

PEV

Phoenix Motor Inc. (NASDAQ:PEV) has launched its Gen 4 retrofit electrification solution for medium-duty vehicles. The solution can be used to electrify a range of current internal combustion engine vehicles. The retrofit solutions aim to alleviate the cost of new EVs and long lead times due to limited availability, allowing fleets to electrify their existing assets, lower capital requirements, and reduce the time to deploy zero-emission alternatives.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:05 am

BTAI

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has provided an update on its late-stage clinical programs and its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film. The company has scheduled meetings with the FDA to discuss the TRANQUILITY and SERENITY III clinical programs and has received two Notices of Allowance from the U.S. Patent and Trademark Office to extend method of use patent protection for sublingual dexmedetomidine.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:03 am

FRLN

Freeline has reported positive initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201, a novel gene therapy candidate for Gaucher disease.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:02 am